4-Methoxy-3-(trifluoromethyl)benzoyl chloride → 4-methoxy-N-{5-[4-(pyridin-3-yloxy)phenyl]-1,3,4-oxadiazol-2-yl}-3-(trifluoromethyl)-benzamide

HRID 387480

反応式

HRID 387480 の反応式
Br.[N:2]1[CH:7]=[CH:6][CH:5]=[C:4]([O:8][C:9]2[CH:14]=[CH:13][C:12]([C:15]3[O:19][C:18]([NH2:20])=[N:17][N:16]=3)=[CH:11][CH:10]=2)[CH:3]=1.[CH3:21][O:22][C:23]1[CH:31]=[CH:30][C:26]([C:27](Cl)=[O:28])=[CH:25][C:24]=1[C:32]([F:35])([F:34])[F:33]>N1C=CC=CC=1.CO>[CH3:21][O:22][C:23]1[CH:31]=[CH:30][C:26]([C:27]([NH:20][C:18]2[O:19][C:15]([C:12]3[CH:11]=[CH:10][C:9]([O:8][C:4]4[CH:3]=[N:2][CH:7]=[CH:6][CH:5]=4)=[CH:14][CH:13]=3)=[N:16][N:17]=2)=[O:28])=[CH:25][C:24]=1[C:32]([F:33])([F:34])[F:35]

参加物

5

反応物 2

HCID 27752984-Methoxy-3-(trifluoromethyl)benzoyl chlorideHCID 686796585-[4-(Pyridin-3-yloxy)phenyl]-1,3,4-oxadiazol-2-amine hydrobromide salt

生成物 1

HCID 591353344-methoxy-N-{5-[4-(pyridin-3-yloxy)phenyl]-1,3,4-oxadiazol-2-yl}-3-(trifluoromethyl)-benzamide収率 16.2%

試薬・触媒・溶媒 2

HCID 887Methanol溶媒HCID 1049Pyridine溶媒

実験手順

5-[4-(Pyridin-3-yloxy)phenyl]-1,3,4-oxadiazol-2-amine hydrobromide salt (167.5 mg, 0.5 mmol) was suspended in 2 mL of anhydrous pyridine. Neat 4-methoxy-3-trifluoromethylbenzoyl chloride (179.0 mg, 0.75 mmol) was added directly into the solution. The reaction mixture formed an orange-red solution with a small amount of white precipitate. It was left to stir for 3 hours. Then it was diluted with ca. 1 mL of MeOH, filtered through 0.22 u syringe filter and purified by reverse phase preparative HPLC using acetonitrile/water mixture containing 0.01% of TFA. Fractions, containing the product, were combined and partitioned between ca. 40 mL of EtOAc and ca. 40 mL of saturated aqueous NaHCO3. The EtOAc layer was washed with brine, dried over anhydrous sodium sulfate and filtered. Solvent was removed in vacuo to give the title product as a yellow solid (37.0 mg). Yield 16.2%.

後処理

  1. customThe reaction mixture formed an orange-red solution with a small amount of white precipitate
  2. waitIt was left
  3. filtrationfiltered through 0.22 u syringe
  4. filtrationfilter
  5. custompurified by reverse phase preparative HPLC
  6. additioncontaining 0.01% of TFA
  7. additionFractions, containing the product
  8. custompartitioned between ca. 40 mL of EtOAc and ca. 40 mL of saturated aqueous NaHCO3
  9. washThe EtOAc layer was washed with brine
  10. dry with materialdried over anhydrous sodium sulfate
  11. filtrationfiltered
  12. customSolvent was removed in vacuo

出典と根拠

ORDレコード
ord-65ea78bf2f4841589ea3f16db7318749
出典データセット
uspto-grants-2013_02
特許番号
US08372971B2

関連ノート

読み込み中…